Penumbra (PEN) Competitors $262.37 -10.87 (-3.98%) Closing price 04/4/2025 03:59 PM EasternExtended Trading$262.35 -0.02 (-0.01%) As of 04/4/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PEN vs. GEHC, PHG, ZBH, SOLV, SNN, STVN, GKOS, BLCO, INSP, and NARIShould you be buying Penumbra stock or one of its competitors? The main competitors of Penumbra include GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Solventum (SOLV), Smith & Nephew (SNN), Stevanato Group (STVN), Glaukos (GKOS), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), and Inari Medical (NARI). These companies are all part of the "medical equipment" industry. Penumbra vs. GE HealthCare Technologies Koninklijke Philips Zimmer Biomet Solventum Smith & Nephew Stevanato Group Glaukos Bausch + Lomb Inspire Medical Systems Inari Medical GE HealthCare Technologies (NASDAQ:GEHC) and Penumbra (NYSE:PEN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment. Does the MarketBeat Community believe in GEHC or PEN? Penumbra received 804 more outperform votes than GE HealthCare Technologies when rated by MarketBeat users. Likewise, 80.27% of users gave Penumbra an outperform vote while only 61.90% of users gave GE HealthCare Technologies an outperform vote. CompanyUnderperformOutperformGE HealthCare TechnologiesOutperform Votes2661.90% Underperform Votes1638.10% PenumbraOutperform Votes83080.27% Underperform Votes20419.73% Do institutionals and insiders believe in GEHC or PEN? 82.1% of GE HealthCare Technologies shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 0.3% of GE HealthCare Technologies shares are owned by company insiders. Comparatively, 5.0% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is GEHC or PEN more profitable? GE HealthCare Technologies has a net margin of 10.13% compared to Penumbra's net margin of 1.17%. GE HealthCare Technologies' return on equity of 25.74% beat Penumbra's return on equity.Company Net Margins Return on Equity Return on Assets GE HealthCare Technologies10.13% 25.74% 6.29% Penumbra 1.17%9.74%7.35% Which has preferable earnings & valuation, GEHC or PEN? GE HealthCare Technologies has higher revenue and earnings than Penumbra. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGE HealthCare Technologies$19.67B1.41$1.99B$4.3313.97Penumbra$1.19B8.46$90.95M$0.34771.66 Does the media refer more to GEHC or PEN? In the previous week, Penumbra had 2 more articles in the media than GE HealthCare Technologies. MarketBeat recorded 27 mentions for Penumbra and 25 mentions for GE HealthCare Technologies. GE HealthCare Technologies' average media sentiment score of 1.20 beat Penumbra's score of 0.78 indicating that GE HealthCare Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GE HealthCare Technologies 18 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Penumbra 15 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, GEHC or PEN? GE HealthCare Technologies has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Do analysts recommend GEHC or PEN? GE HealthCare Technologies currently has a consensus price target of $97.73, suggesting a potential upside of 61.51%. Penumbra has a consensus price target of $294.47, suggesting a potential upside of 12.24%. Given GE HealthCare Technologies' higher probable upside, equities analysts plainly believe GE HealthCare Technologies is more favorable than Penumbra.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GE HealthCare Technologies 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.75Penumbra 0 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.88 SummaryPenumbra beats GE HealthCare Technologies on 10 of the 18 factors compared between the two stocks. Remove Ads Get Penumbra News Delivered to You Automatically Sign up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PEN vs. The Competition Export to ExcelMetricPenumbraSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$10.11B$3.99B$5.26B$17.80BDividend YieldN/A40.98%4.89%3.82%P/E Ratio771.6627.2321.4229.94Price / Sales8.4646.11355.0024.19Price / Cash105.0151.7738.1817.54Price / Book8.785.706.234.13Net Income$90.95M$67.02M$3.21B$1.02B7 Day Performance-1.79%-8.78%-8.47%-8.73%1 Month Performance-5.50%-9.81%-4.47%-9.91%1 Year Performance17.15%5.52%2.76%-5.10% Penumbra Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PENPenumbra4.5864 of 5 stars$262.37-4.0%$294.47+12.2%+17.2%$10.11B$1.19B771.663,900Insider TradeAnalyst RevisionNews CoverageGap DownGEHCGE HealthCare Technologies4.0263 of 5 stars$80.71+0.9%$98.75+22.4%-31.6%$36.91B$19.67B18.6450,000Positive NewsPHGKoninklijke Philips3.752 of 5 stars$25.40-1.0%N/A+10.0%$23.87B$18.02B-30.2378,200ZBHZimmer Biomet4.5798 of 5 stars$113.33+1.2%$124.15+9.5%-15.6%$22.56B$7.68B25.4718,000Analyst RevisionNews CoveragePositive NewsSOLVSolventum1.2613 of 5 stars$76.02+1.7%$79.86+5.0%-5.5%$13.15B$8.25B27.6422,000News CoverageSNNSmith & Nephew2.8246 of 5 stars$28.39+1.2%$27.00-4.9%+7.6%$12.41B$5.81B13.1420,100Positive NewsSTVNStevanato Group1.3173 of 5 stars€20.37+0.4%N/AN/A$6.17B$1.10B43.344,650Positive NewsGKOSGlaukos3.8726 of 5 stars$98.49-3.4%$163.25+65.8%-13.6%$5.57B$383.48M-34.32780News CoveragePositive NewsGap DownBLCOBausch + Lomb3.7062 of 5 stars$14.50+2.6%$19.18+32.3%-26.6%$5.11B$4.79B-15.9312,500Analyst ForecastNews CoverageHigh Trading VolumeINSPInspire Medical Systems4.8254 of 5 stars$159.60+1.5%$226.70+42.0%-36.5%$4.75B$802.80M92.261,246News CoveragePositive NewsNARIInari Medical0.9336 of 5 stars$79.97flat$68.00-15.0%N/A$4.68B$493.63M-59.24800 Remove Ads Related Companies and Tools Related Companies GE HealthCare Technologies Competitors Koninklijke Philips Competitors Zimmer Biomet Competitors Solventum Competitors Smith & Nephew Competitors Stevanato Group Competitors Glaukos Competitors Bausch + Lomb Competitors Inspire Medical Systems Competitors Inari Medical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PEN) was last updated on 4/6/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Penumbra, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Penumbra With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
